Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
86 Results for "
endogenous compounds
" in MedChemExpress (MCE) Product Catalog:
Products (86)
86 Results for "endogenous compounds" in MCE Product Catalog:
Cat. No.: HY-W782193
CAS No.: 55320-91-7
Synonyms: 6-Methyl-5-hepten-2-one-d5
Cat. No.: HY-170929
CAS No.: 2930726-89-7
Target:
Research Areas:
EMT inhibitor-3 (compound 11i) is a epithelial-mesenchymal transition (EMT) inhibitor. EMT inhibitor-3 inhibits neuroblastoma SK-N-SH cells with an IC50 of 2.5 μM. EMT inhibitor-3 inhibits SK-N-SH cell proliferation, migration, and invasion. EMT inhibitor-3 increases the Bax/Bcl-2 protein expression ratio, promotes Cytochrome C ( HY-125857) release from mitochondria, and activates caspases 9 and caspases 3, inducing mitochondria-mediated endogenous tumor cell Apoptosis. EMT inhibitor-3 is potential for cancer research .
Cat. No.: HY-173271
CAS No.: 3060887-25-1
Target:
Research Areas:
GHSR-1a agonist-1 (Compound 4b) is an orally active agonist of the human growth hormone secretagogue receptor 1a (GHSR-1a), with an EC50 of 0.49 nM. GHSR-1a agonist-1 can effectively stimulate the release of endogenous growth hormone by activating GHSR-1a. GHSR-1a agonist-1 administered orally at a dose as low as 0.1 mg/kg can increase the body weight and body length of 4-week-old rats. GHSR-1a agonist-1 can be used in the research field of growth and development retardation in children .
Target:
Cat. No.: HY-N15363
CAS No.: 85202-13-7
Category:
Target:
Target:
Cat. No.: HY-L030
765 compounds
The composition of endogenous metabolite compounds is affected by the upstream influence of the proteome and genome as well as environmental factors, lifestyle factors, medication, and underlying disease. Therefore, metabolites have been described as proximal reporters of disease because their abundances in biological specimens are often directly related to pathogenic mechanisms. In more recent years, metabolomics approach has been adopted or suggested to be used in various research areas including drug discovery, neurosciences, agriculture, food and nutrition, and environmental sciences.
MCE owns a unique collection of 765 human endogenous metabolites, all of which are derived from human issues. This library is a powerful tool for metabonomics research and metabolism-related drug discovery.
Cat. No.: HY-E72102
Target:
Research Areas:
Human CYP3A4, Reductase+b5 refers to a near-physiological recombinant microsomal system co-expressed in insect cells, consisting of human cytochrome P450 3A4, NADPH-P450 oxidoreductase (CPR) and cytochrome b5. Human CYP3A4 is a human cytochrome P450 subtype belonging to the CYP3 family, as well as a major metabolic enzyme. It is predominantly expressed in human liver and intestine, metabolizes a variety of active compounds, and activates multiple procarcinogens .
Cat. No.: HY-12374
CAS No.: 1314944-07-4
Target:
Research Areas:
KBP-5493 (compound D) is an endogenous metabolite that can be detected in urine and plasma.
Cat. No.: HY-186179
CAS No.: 37491-98-8
Category:
Target:
Cat. No.: HY-180734
CAS No.: 22467-93-2
Category:
Target:
Cat. No.: HY-167717
CAS No.: 191791-65-8
Synonyms: (Rac)-F 12511
Target:
Research Areas:
(Rac)-Eflucimibe ((Rac)-F 12511) is an ACAT inhibitor with endogenous hypercholesterolemia modulating activity. (Rac)-Eflucimibe has shown high potency and efficacy as an anti-hypercholesterol compound in different hypercholesterolemia animal models .
Cat. No.: HY-N22000
CAS No.: 14379-32-9
Category:
Target:
Cat. No.: HY-L207
661 compounds
Metabolomics is the large-scale study of cellular metabolic complement, with proven utility in both basic and applied studies of plants, microorganisms, and mammals. As an important tool for the study of complex biological systems, metabolomics monitors the complex molecular networks that exist in the natural flow of information from genes to mRNA and proteins to organisms. The metabolome is composed of biomolecules that most closely resemble the phenotype of an organism, and changes in its composition can easily lead to the production of diseases. Therefore, metabolomics has received much attention in drug target discovery, drug response and translational research of disease mechanisms. Mass spectrometry-based metabolomics methods can simultaneously detect and quantify thousands of metabolite signatures, thereby characterizing the pathophysiological mechanisms of various biomedical symptoms.
MCE can provide 661 mass spectrometry human endogenous metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.
Cat. No.: HY-N15457
CAS No.: 126576-14-5
Target:
Cat. No.: HY-W746295
Cat. No.: HY-116184
CAS No.: 1604034-71-0
Target:
Research Areas:
PF-05387252 is a potent and selective IRAK4 inhibitor with the activity of inhibiting endogenous TLR signaling pathways. PF-05387252 has shown anti-inflammatory activity in experimental models and may have potential clinical application value in inhibiting psoriasis. Although PF-05387252 and its related compounds have shown anti-inflammatory effects in animal models, their efficacy in inhibiting psoriasis has not yet been verified .
Cat. No.: HY-125059
CAS No.: 865531-74-4
Target:
Research Areas:
PTC-510 Free base is a compound that selectively inhibits hypoxia-induced VEGF expression in tumor cells. PTC-510 Free base demonstrates potent activity in reducing endogenous VEGF production under hypoxic conditions. PTC-510 Free base has been shown to control tumor growth effectively while minimizing toxicity. PTC-510 Free base represents a novel therapeutic strategy to address the limitations of current anti-VEGF therapies.
Cat. No.: HY-158616
CAS No.: 1286479-53-5
Cat. No.: HY-187390
Research Areas:
BRD4 RIMTAC-1 is a BRD4 PROTAC degrader based on the RIPK1-mediated targeted chimera (RIMTAC) technology. It hijacks the endogenous RIPK1-VHL complex via the RIPK1 inhibitor moiety to indirectly recruit the VHL E3 ligase, forming a BRD4-Compound 10-RIPK1-VHL quaternary complex, and degrades BRD4 through the ubiquitin-proteasome system (UPS). BRD4 RIMTAC-1 exhibits selectivity over other BET proteins, induces concentration- and time-dependent, reversible post-translational degradation of BRD4 without altering the target mRNA level. BRD4 RIMTAC-1 potently induces endogenous BRD4 degradation in RAW264.7 and HEK-293T cells, with DC50 values of 179.1 nM and 54.12 nM, respectively. BRD4 RIMTAC-1 can be used for the research of cancer and inflammation-related diseases .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
